Pharmacogenetics

For a personalized treatment

View study
For a personalized treatment For a personalized treatment

Clinical experience

Integrated by clinicians and pharmacists specialized in the field of clinical pharmacology and physicians specialized in internal medicine, cardiology, neurology, clinical geneticists, biologists and bioinformaticians

Knowledge Management

Expert detailed curation of Scientific Literature and recommendations of the main clinical pharmacogenetics guidelines

Sequencing panel design

Deep sequencing NGS approach with an in-house designed panel. Allows for the study of highly polymorphic genes and structural variants (CNVs)

Pharmacogenetics Global Panel

[85 DRUGS, 17 GENES AND 935 GENETICS REGIONS]

The pharmacogenetics global panel analyzes genetic-based variation in response to different drugs within a single panel. The study includes all drugs and genetic variants included in the recommendations of the main clinical pharmacogenetics guidelines.

The global pharmaHIC panel provides information on treatment individualization for 85 drugs, 17 genes, and 935 genetic regions.

TAT [turnaround time]: 5 weeks

Study request form
Informed consent
 

 

STUDIED DRUGS:

Central Nervous System

Antidepressants

Selective serotonin reuptake inhibitors
(SSRIs): citalopram, escitalopram, fluvoxamine, paroxetine, sertraline.
Selective serotonin and noradrenalin reuptake inhibitor (SNRIs): venlafaxine, desvenlafaxine, duloxetine.
Tricyclic antidepressants (TCA): amitriptyline, clomipramine, doxepin, imipramine, nortriptyline, trimipramine.
Other antidepressants: mirtazapine, moclobemide, vortioxetine, nefazodone.

Antipsychotics

First generation antipsychotics (FGA): haloperidol, zuclopenthixol, pimozide, perphenazine.
Second generation antipsychotics (SGA): aripiprazole, clozapine, olanzapine, risperidone.

Antiepileptics: phenytoine, carbamazepine, oxcarbazepine.

Centrally acting sympathomimetics: atomoxetine.

Benzodiazepines: diazepam, clobazam, brivaracetam.

Digestive System

Antiemetic 5-HT3 antagonists: ondansetron, tropisetron.

Gastric protectors (Proton pump inhibitors): esomeprazole, lansoprazole, omeprazole, pantoprazole, rabeprazole.

Analgesics

Codeine, tramadol, oxyodone.

Antineoplastic and immunosuppressive agents

Fluoropyrimidines: 5-fluorouracil, capecitabine.

Topoisomerase inhibitors: irinotecan.

Hormone therapy: tamoxifen.

Thiopurines: azathioprine, mercaptopurine, thioguanine.

Calcineurin inhibitors: tacrolimus.

Anthracyclines: doxorubicin, daunorubicin.

Platins: cisplatin.

Cardiovascular system

Antiplatelet agents: clopidogrel, ticagrelor.

Oral anticoagulants: acenocoumarol, warfarin, apixaban, rivaroxaban.

Hypolipidemic agents: atorvastatin, fluvastatin, lovastatin, pitavastatin, simvastatin, rosuvastatin, pravastatin.

Beta blockers: bisoprolol, carvedilol, metoprolol, nebivolol, propranolol.

Antiarrhythmics: amiodarone, dronedarone, flecainide, propafenone.

Infectious diseases

Antifungal agents: voriconazole.

Antiviral agents-HCV: peginterferon alfa-2A, peginterferon alfa-2B, ribavirin.

Antiretroviral agents-HIV: abacavir, atazanavir.

Endocrine system and metabolism

Oral antidiabetics

Sulfonylureas: gliclazide, glimepiride, glibenclamide, tolbutamide.

Hypouricemic agents: allopurinol, rasburicase.

Contraceptives:: estrogen oral contraceptives.

CYP1A2 (16 alleles, 14 regions) CYP2C9 (13 alleles, 14 regions) CYP3A4 (22 alleles, 20 regions)
F5 (1 allele, 1 region) HLA-A (1 allele, 1 region) IFNL3 (1 allele, 1 region)
SLC28A3 (1 allele, 1 region) TPMT (12 alleles, 7 regions) UGT1A6 (6 alleles, 4 regions)
CYP2C19 (15 alleles, 15 regions) CYP2D6 (28 alleles, 24 regions, CNVs studies) DPYD (12 alleles, 10 regions)
G6PD (212 alleles, 173 regions) HLA-B (2932 alleles, 627 regions) RARG (1 allele, 1 regions)
SLCO1B1 (19 alleles, 15 regions) UGT1A1 (8 alleles, 6 regions) VKORC1 (1 allele, 1 region)

 

Health in Code’s Genetic Studies:

Este sitio web utiliza cookies para que usted tenga la mejor experiencia de usuario. Si continúa navegando está dando su consentimiento para la aceptación de las mencionadas cookies y la aceptación de nuestra política de cookies, pinche el enlace para mayor información. Más información

The cookie settings on this website are set to "allow cookies" to give you the best browsing experience possible. If you continue to use this website without changing your cookie settings or you click "Accept" below then you are consenting to this.

Close